A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma - Related Studies

A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma

This study is currently recruiting participants.

Study NCT00315731. Last updated on June 9, 2008. Information provided by GlaxoSmithKline

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Non-Hodgkin's Lymphoma
		Follicular Lymphoma
		Diffuse Large Cell Lymphoma

2	Additional conditions recognized in this trial
		Lymphoma
		Lymphoma, Follicular
		Lymphoma, Large B-Cell, Diffuse
		Lymphoma, Non-Hodgkin

3	More general conditions related to this trial
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoma, B-Cell
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

4	Additional drug interventions recognized in this trial
		Antibodies, Monoclonal
		Iodine
		Iodine-131 anti-B1 antibody

5	More general drug interventions related to this trial
		Anti-Infective Agents
		Anti-Infective Agents, Local
		Antineoplastic Agents
		Growth Substances
		Immunologic Factors
		Micronutrients
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses
		Trace Elements

6	Sponsors listed in this trial
		GlaxoSmithKline